6855 — Ascentage Pharma International Share News
0.000.00%
Last trade - 00:00- HK$11.38bn
- HK$11.63bn
- CNY574.12m
Brief: Ascentage Pharma Group International Says Loss For Year Up 12.8% To RMB882.9 Million
Over a dozen Chinese-based firms say they have minimal exposure to SVB (updated)
Ascentage Pharma drops most in nearly 2-yrs on $70 mln discounted share sale
Brief: Ascentage Pharma Group International Says Co To Place 22.5 Mln Shares Of Co
Brief: Ascentage Pharma Delivers Oral Presentations On Chinese Studies of Olverembatinib
Brief: Ascentage Pharma Group International Says It Got China IND Approval For Phase I Study Of APG-5918
Brief: Ascentage Pharma Group International Says HY Loss Attributable RMB406.7 Mln
Brief: Ascentage Pharma And Tanner Pharma Group Initiate A Global Innovative Named Patient Program
Brief: Ascentage Pharma Group International Announces Study Of Olverembatinib Approved In Canada
Brief: Ascentage Pharma Group International Says China's Nmpa Accepted & Granted Priority Review Designation To NDA For Olverembatinib
Brief: Ascentage Pharma Announces IND Clearance By The US FDA For First-In-Human Study Of Novel EED Inhibitor APG-5918
Brief: Ascentage Pharma Group International Announces CDE's Approval For Phase II Study Of Lisaftoclax
Brief: Clover Biopharmaceuticals's Unit Enters Collaboration Agreement With Jiangsu Ascentage Pharma
Brief: Clover And Ascentage Pharma Announce Clinical Collaboration
Brief: Ascentage Pharma Appoints Yiqing Chen As CFO
Brief: Ascentage Pharma Group International Appointed Chen Yiqing As CFO
Brief: Ascentage Pharma Group International Says Unit's Drug Candidate Olverembatinib Approved By NMPA
Brief: Ascentage Pharma Group International Says European Commission Granted Its Core Drug Candidate HQP1351 (Olverembatinib) Orphan Designation
Brief: Ascentage Pharma Group Repurchased Aggregate Of 76,800 Shares Of Co For HK$2.2 Mln